What is HC Wainwright’s Forecast for CRDL FY2026 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities research analysts at HC Wainwright increased their FY2026 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.25) for the year, up from their previous forecast of ($0.27). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ FY2027 earnings at ($0.31) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last announced its earnings results on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07).

CRDL has been the subject of a number of other research reports. Wall Street Zen raised Cardiol Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, April 5th. Canaccord Genuity Group restated a “buy” rating and issued a $8.00 price target on shares of Cardiol Therapeutics in a research note on Monday, April 6th. Finally, raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.50.

Cardiol Therapeutics Price Performance

Shares of NASDAQ CRDL opened at $1.36 on Thursday. The firm has a market cap of $152.08 million, a price-to-earnings ratio of -4.86 and a beta of 0.77. The stock’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.10. Cardiol Therapeutics has a one year low of $0.88 and a one year high of $1.71.

Hedge Funds Weigh In On Cardiol Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRDL. Bank of America Corp DE lifted its position in shares of Cardiol Therapeutics by 136.2% during the 2nd quarter. Bank of America Corp DE now owns 26,455 shares of the company’s stock valued at $36,000 after acquiring an additional 15,255 shares during the period. Simplex Trading LLC increased its position in shares of Cardiol Therapeutics by 96.9% in the fourth quarter. Simplex Trading LLC now owns 32,197 shares of the company’s stock worth $31,000 after purchasing an additional 15,842 shares during the period. Security National Bank of Sioux City Iowa IA acquired a new position in Cardiol Therapeutics in the fourth quarter valued at about $31,000. Boyer Financial Services Inc. bought a new stake in Cardiol Therapeutics during the fourth quarter worth about $33,000. Finally, Susquehanna International Group LLP lifted its position in Cardiol Therapeutics by 366.5% during the third quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after purchasing an additional 73,375 shares during the period. 12.49% of the stock is owned by institutional investors and hedge funds.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.